MedPageToday
MedPage Today) — BARCELONA — The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic arthritis (PsA), demonstrating superiority over placebo for most of its endpoints, according to a presentation…
Read More
Fresh Data Bolster TYK2 Blocker for Psoriatic Arthritis
Margarett Grisby
08:23
MedPage Today) — BARCELONA — The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic arthritis (PsA), demonstrating superiority over placebo for most of its endpoints, according to a presentation…
